Not Signed In -
Galantamine |
Reminyl |
Clinical Trial: Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer’s Disease
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Alzheimer's Disease | Drug: galantamine ER | Phase III |
MedlinePlus related topics: Alzheimer's Caregivers; Alzheimer's Disease
Genetics Home Reference related topics: Alzheimer disease
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety Study
Official Title: Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer’s Disease
Further Study Details:
Expected Total Enrollment: 100
Study start: May 2004; Expected completion: November 2004
Eligibility
Ages Eligible for Study: 60 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Diagnosis of Alzheimer's Disease
Location and Contact Information
California
California Neuroscience Research, Sherman Oaks, California, 91403, United States; Recruiting
Susie Tanamly 818-990-2671
Thomas Shiovitz, MD, Principal Investigator
Thomas Shiovitz, MD, Principal Investigator
Institute on Aging Research Center, San Francisco, California, 94118, United States; Recruiting
Hazel Outlaw 415-750-4180 Ext. 177
Richard Moore, MD, Principal Investigator
Richard Moore, MD, Principal Investigator
Florida
University of Florida Brain Institute, Gainsville, Florida, 32611, United States; Recruiting
Shelia O'Hara 352-392-3681
Josepha Cheong, MD, Principal Investigator
Josepha Cheong, MD, Principal Investigator
Hawaii
John A Burns School of Medicine, Honolulu, Hawaii, 96817, United States; Recruiting
Dennis Shewell 808-523-8461
Patricia L Blanchette, MD, Principal Investigator
Patricia L Blanchette, MD, Principal Investigator
New Jersey
Hunterdon Medical Center Senior Services, Flemington, New Jersey, 08822, United States; Recruiting
Jennifer Hamil 908-788-6373
Sandra Siegel 909-788-6373
Kumar Nanjagowder, MD, Principal Investigator
Sandra Siegel 909-788-6373
Kumar Nanjagowder, MD, Principal Investigator
Ohio
Valley Medical Primary Care, Centerville, Ohio, 45459, United States; Recruiting
Debra McElhaney, MA 937-208-8282
Meenakshi Patel, MD, Principal Investigator
Meenakshi Patel, MD, Principal Investigator
Ohio State University Memory Disorders Clinic, Columbus, Ohio, 43210, United States; Recruiting
Jennifer Warner 614-293-8531
Jennifer Knick 614-293-8531
Douglas Scharre, MD, Principal Investigator
Jennifer Knick 614-293-8531
Douglas Scharre, MD, Principal Investigator
Pennsylvania
Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States; Recruiting
Peg DeLillis 717-531-7240
Joan Busner 717-531-7240
Paul Kettl, MD, Principal Investigator
Joan Busner 717-531-7240
Paul Kettl, MD, Principal Investigator
Rhode Island
Butler Hospital, Providence, Rhode Island, 02906, United States; Recruiting
Margy Bowker, RN 401-455-6402
Steven Salloway, MD, Principal Investigator
Steven Salloway, MD, Principal Investigator
South Carolina
Medical University of South Carolina, Charleston, South Carolina, 29406, United States; Recruiting
Don Bagwell 843-740-1592 Ext. 12
Warachal Faison, MD, Principal Investigator
Warachal Faison, MD, Principal Investigator
Tennessee
Meharry Medical College, Nashville, Tennessee, 37208, United States; Recruiting
Joan Ross 615-327-6565
Jerry Duncan, MD, Principal Investigator
Jerry Duncan, MD, Principal Investigator
Texas
Texas Tech University Health Sciences Center, Lubbock, Texas, 79416, United States; Recruiting
Margie Lance-Fish 806-743-2587
Jimmy Garza 806-743-2587
Randolph Schiffer, MD, Principal Investigator
Jimmy Garza 806-743-2587
Randolph Schiffer, MD, Principal Investigator
More Information
Study ID Numbers: GAL-ALZ-303
Record last reviewed: July 2004
Last Updated: October 13, 2004
Record first received: May 12, 2004
ClinicalTrials.gov Identifier: NCT00082602
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: July 2004
Last Updated: October 13, 2004
Record first received: May 12, 2004
ClinicalTrials.gov Identifier: NCT00082602
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
